RESCINDED
Notice Number: NOT-AI-18-024
Key Dates
Release Date: March 28, 2018
Issued by
National Institute of Allergy and Infectious Diseases (NIAID)
Purpose
In FY2016-2018 NIAID supported high priority immunology grants beyond the institute’s payline to address a decline in NIAID immunology applications and to maintain a robust portfolio of immunology research (PAS-15-055, “High Priority Immunology Grants”). Based on the success of this program NIAID will continue to support a small number of investigator-initiated R01 immunology applications received in response to PA-18-484 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) that score beyond the Institute’s payline.
NIAID is the lead NIH institute for research in fundamental immunology and is committed to supporting a comprehensive portfolio of investigator-initiated R01 studies as the basis of innovation and foundation for applied research in immunology and immune-mediated and infectious diseases. The NIAID strategic plan highlights the central role of immunology in the NIAID public health mission, providing the scientific basis for new, more effective approaches that include rational development of vaccines and adjuvants, manipulation of immune tolerance, and molecular understanding of the precise mechanisms of human immune regulation.
Examples of scientific interest include, but are not limited to:
Inquiries
Please direct all inquiries to:
Johanna S. Schneider, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3558
Email: [email protected]